This technology describes using 10-chloro-7H-benzimidazo[2,1-a]benzo[de]Iso-quinolin-7-one (10-Cl-BBQ) and its analogs to treat type 1 diabetes, graft versus host disease and potentially other autoimmune diseases . In vivo studies in using non-obese diabetic (NOD) mice clearly demonstrated that low dose treatment during the early stages of type 1 diabetes prevented the autoimmune destruction of pancreatic beta cells and consequently prevented the progression and development full-blown type 1 diabetes. Additional studies have established the effectiveness of 10-Cl-BBQ in preventing the development of acute graft-vs-host disease, a debilitating immune-mediated condition associated with organ and bone-marrow transplantation.
Features & Benefits
Background of Invention
Lack of effective, non-toxic drug therapies for prevention and treatment of autoimmune diseases is a significant problem for the millions of people that suffer from such conditions. Accordingly, the present invention is a method of treating immune-mediated diseases comprising the step of administering a therapeutically effective amount of an aryl hydrocarbon receptor ligand. Patent pending and available for exclusive licensing.